Cardiovascular health
- 04 Dec 2023
- 1 Minute to read
- Print
- PDF
Cardiovascular health
- Updated on 04 Dec 2023
- 1 Minute to read
- Print
- PDF
Article summary
Did you find this summary helpful?
Thank you for your feedback
- Evidence suggests that HRT (oestrogen with or without a progestogen) started before the age of 60 years or within 10 years of the last menstrual period, is associated with a reduction in atherosclerosis progression, coronary heart disease and death from cardiovascular causes.
- This has been termed the cardiovascular timing hypothesis or the cardiovascular window of opportunity.
- Women with POI should be advised to take hormone replacement at least until the average age of the menopause to lower the risk of long-term health sequelae such as cardiovascular disease.
References and Further Information:
- Hamoda H, Panay N, Pedder H et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Found on page 187. Post Reprod Health 2020.
- Boardman H, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews 3: CD002229. 2015.
- Menopause Practice Standards produced by the British Menopause Society (BMS), Royal College of Obstetricians and Gynaecologists (RCOG), Society for Endocrinology (SfE), Faculty of Sexual and Reproductive Health (FSRH), Faculty of Pharmaceutical Medicine (FPM) and Royal Pharmaceutical Society (RPS) 2022. Found on page 12.
Was this article helpful?